Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 41 | 160 | 58 | 188 |
| Operating expenses: | ||||
| Research and development (Includes $2, $11, $2 and $6 from a related party) | 113 | 139 | 235 | 261 |
| General and administrative(Includes $—, $2, $— and $2 from a related party) | 24 | 29 | 53 | 57 |
| Total operating expenses | 137 | 168 | 288 | 318 |
| Loss from operations | (96) | (8) | (230) | (130) |
| Non-operating income (expense): | ||||
| Interest and other income, net | 8 | 10 | 17 | 21 |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's G&A?
- Arcus Biosciences (RCUS) reported G&A of $24M in Q2 2026.
- How has Arcus Biosciences's G&A changed year-over-year?
- Arcus Biosciences's G&A decreased by 17.2% year-over-year, from $29M to $24M.
- What is the long-term trend for Arcus Biosciences's G&A?
- Over 4 years (2021 to 2025), Arcus Biosciences's G&A has grown at a 11.2% compound annual growth rate (CAGR), from $72M to $110M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Arcus Biosciences's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude